|
Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders
|
May 2012
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
|
May 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.
|
Feb 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Expression of nucleoside metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
|
Nov 2013
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria
|
Jan 2021
|
Leukemia
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
|
Sep 2014
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
|
Jul 2020
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes
|
Jun 2017
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia
|
Feb 2013
|
Leukemia
|
aplastic anemia
|
|
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
|
Jun 2016
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
